Stimulation of the T cell receptor leads to the activation of NFkB and
NFAT signaling modules which play a key role in T cell receptor
signaling.

There are today 242 companies plus partners developing 339 T cell
receptor pathway targeting drugs in 1232 developmental projects in
cancer. In addition, there are 6 suspended drugs and the accumulated
number of ceased drugs over the last years amount to another 173 drugs.

T-Cell Receptor Signaling Pathway In Oncology Drug Pipeline Update lists
all drugs and gives you a progress analysis on each one of them.
Identified drugs are linked to 201 different targets. All included
targets have been cross-referenced for the presence of mutations
associated with human cancer. To date 196 out of the 199 studied drug
targets so far have been recorded with somatic mutations.

The software application lets you narrow in on these mutations and links
out to the mutational analysis for each of the drug targets for detailed
information. All drugs targets are further categorized on in the
software application by 46 classifications of molecular function and
with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

Drug Pipeline Update at a Glance

Investigators

Includes more than 242 principal companies plus their collaborators.
There is direct access from inside the application to web pages of all
principal companies.

Drug name & Synonyms

Lists commercial, generic and code names for drugs.

Developmental stage

This Drug Pipeline Update contains 339 T cell receptor pathway
targeting drugs in development, which have a total of 1232
developmental projects in cancer. In addition there are suspended and
ceased drugs.

Pipeline Breakdown According to Number of Drugs

Marketed # 34

Registered # 1

Pre-registration # 3

Phase III # 38

Phase II # 113

Phase I # 155

Preclinical # 167

No Data # 4

Suspended # 6

Ceased # 173

Indications

Included T cell receptor pathway targeting drugs are also in
development for 175 other indications, where of 116 are different
cancer indications.